Ipek Erdogan-Trinkaus - 10 Nov 2026 Form 4 Insider Report for Eton Pharmaceuticals, Inc. (ETON)

Reporting relationship: Chief Commercial Officer
Issuer ticker: ETON
Reported as of: 10 Nov 2026
Net transaction value: -$235,937
SEC form: 4
Accepted by SEC: 12 Nov 2026, 16:45:21 UTC
Prior SEC filing: 04 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Judith Matthews

Filing notes and source

Key filing fact

Ipek Erdogan-Trinkaus filed Form 4 for Eton Pharmaceuticals, Inc. (ETON) on 12 Nov 2026.

Key facts

This page summarizes Ipek Erdogan-Trinkaus's Form 4 filing for Eton Pharmaceuticals, Inc. (ETON).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Nov 2026, 16:45.

Change

Previous filing in this sequence was filed on 04 Aug 2026.
Current net transaction value: -$235,937.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002047026 Primary reporting owner

Erdogan-Trinkaus Ipek

Relationship: Chief Commercial Officer
Address: C/O ETON PHARMACEUTICALS, INC., 21925 W. FIELD PARKWAY, SUITE 235, DEERPARK
Signature: /s/ Judith Matthews
Signature date: 12 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ETON transaction

Common Stock

Options Exercise

Transaction value
Shares: +3,500
Change %: +86%
Price: $15.47^*
Shares after: 7,581
Date: 10 Nov 2026
Ownership: Direct

ETON transaction

Common Stock

Sale

Transaction value: -$157,198
Shares: -2,340
Change %: -31%
Price: $67.18
Shares after: 5,241
Date: 10 Nov 2026
Ownership: Direct
Footnotes: F2, F3

ETON transaction

Common Stock

Sale

Transaction value: -$78,739
Shares: -1,160
Change %: -22%
Price: $67.88
Shares after: 4,081
Date: 10 Nov 2026
Ownership: Direct
Footnotes: F2, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ETON transaction Derivative

Employee Stock Option

Options Exercise

Transaction value
Shares: -3,500
Change %: -8.6%
Price: $0.000000^*
Shares after: 37,155
Date: 10 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,500
Exercise price: $15.47
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The shares subject to the option vest in 48 equal monthly installments from the date of grant (1-12-2026) until fully vested and exercisable on January 12, 2030.

Footnote F2

The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

Footnote F3

The shares were sold in multiple trades at prices ranging from $66.645 to $67.62. The price reported above reflects the weighted average sales price.

Footnote F4

The shares were sold in multiple trades at prices ranging from $67.6825 to $68.075. The price reported above reflects the weighted average sales price.

SEC remarks

The signing person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.